Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by nozzpackon Dec 02, 2021 10:01am
164 Views
Post# 34189549

RE:4 Quarter Trends in Absorica and Absorica +

RE:4 Quarter Trends in Absorica and Absorica + When I look over all of this, I see Q4 being about the same level it was in Q4 of 2020 which is $6 million US.

In addition, leasing its office space ( which cost us for inducement  $2.2 million in Q3 ) will begin to decrease operating costs in Q4 and going forward.

I expect about 1.5 cent per quarter gain in EPS due to this factor.

Once again, we saw  knee jerk over selling in Q3.

Cash levels will also increase substantially in Q4 to nearly $1 per share.

At some point, one of two moves will be made by Mull.

Either we use the cash hoard to acquire or we will be sold.

Either way, those who buy now will be astute winners..
<< Previous
Bullboard Posts
Next >>